Skip to main content
. 2007 Jan 12;63(6):732–740. doi: 10.1111/j.1365-2125.2006.02836.x

Table 2.

The blood glucose response to 0.875 mg oral glibenclamide in 12 healthy volunteers after 3 days of pretreatment with clarithromycin (250 mg twice daily), placebo (control), or grapefruit juice (200 ml thrice daily)

Blood glucose variable Placebo (control) phase Clarithromycin phase Grapefruit juice phase
Decremental AUC(0,3 h) (mmol l−1 h) 3.11 ± 1.57 2.41 ± 1.47 2.08 ± 1.57
Mean difference from control phase (95% CI) −0.70 (−2.31, 0.92) −1.03 (−2.78, 0.73)
Decremental AUC(0,7 h) (mmol l−1 h) 5.28 ± 3.25 3.79 ± 2.32 3.38 ± 4.07
Mean difference from control phase (95% CI) −1.48 (−4.72, 1.76) −1.89 (−6.33, 2.54)
Maximum increase (mmol l−1) 0.80 ± 0.70 1.29 ± 0.89 1.07 ± 0.75
Mean difference from control phase (95% CI) 0.49 (−0.41, 1.39) 0.27 (−0.47, 1.00)
Maximum decrease (mmol l−1) 2.47 ± 0.70 2.49 ± 0.47 2.18 ± 0.71
Mean difference from control phase (95% CI) 0.03 (−0.76, 0.81) −0.28 (−1.18, 0.61)

Data are mean values ± SD unless otherwise shown. AUC(0,3 h), area under curve from time zero to 3 h; AUC(0,7 h), area under curve from time zero to 7 h.